» Articles » PMID: 25419740

A Community Computational Challenge to Predict the Activity of Pairs of Compounds

Abstract

Recent therapeutic successes have renewed interest in drug combinations, but experimental screening approaches are costly and often identify only small numbers of synergistic combinations. The DREAM consortium launched an open challenge to foster the development of in silico methods to computationally rank 91 compound pairs, from the most synergistic to the most antagonistic, based on gene-expression profiles of human B cells treated with individual compounds at multiple time points and concentrations. Using scoring metrics based on experimental dose-response curves, we assessed 32 methods (31 community-generated approaches and SynGen), four of which performed significantly better than random guessing. We highlight similarities between the methods. Although the accuracy of predictions was not optimal, we find that computational prediction of compound-pair activity is possible, and that community challenges can be useful to advance the field of in silico compound-synergy prediction.

Citing Articles

HPRNA: Predicting synergistic drug combinations for angina pectoris based on human pathway relationship network algorithm.

Zhou M, Xu M, Zhang X, Xing X, Li Y, Wang G PLoS One. 2025; 20(2):e0318368.

PMID: 39913435 PMC: 11801531. DOI: 10.1371/journal.pone.0318368.


A human metabolic map of pharmacological perturbations reveals drug modes of action.

Schuhknecht L, Ortmayr K, Janes J, Blasi M, Panoussis E, Bors S Nat Biotechnol. 2025; .

PMID: 39875672 DOI: 10.1038/s41587-024-02524-5.


Artificial intelligence-driven identification and mechanistic exploration of synergistic anti-breast cancer compound combinations from L.- Hand.-Mazz. herb pair.

Feng C, Cheng J, Sun M, Qiao C, Feng Q, Fang N Front Pharmacol. 2025; 15():1522787.

PMID: 39840098 PMC: 11747269. DOI: 10.3389/fphar.2024.1522787.


Computational frameworks transform antagonism to synergy in optimizing combination therapies.

Chen J, Lin A, Jiang A, Qi C, Liu Z, Cheng Q NPJ Digit Med. 2025; 8(1):44.

PMID: 39828791 PMC: 11743742. DOI: 10.1038/s41746-025-01435-2.


Synergistic combinations of for myocardial infarction treatment: network pharmacology and quadratic optimization approach.

Wang W, Fan X, Wei X, Chai W, Li F, Gao K Front Pharmacol. 2024; 15:1466208.

PMID: 39717556 PMC: 11663646. DOI: 10.3389/fphar.2024.1466208.


References
1.
Hoshida Y . Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One. 2010; 5(11):e15543. PMC: 2990751. DOI: 10.1371/journal.pone.0015543. View

2.
Stein G, Gurwith M . Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. Clin Pharm. 1984; 3(6):591-9. View

3.
Green M, Monti S, Rodig S, Juszczynski P, Currie T, ODonnell E . Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-77. PMC: 2995356. DOI: 10.1182/blood-2010-05-282780. View

4.
Cokol M, Chua H, Tasan M, Mutlu B, Weinstein Z, Suzuki Y . Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011; 7:544. PMC: 3261710. DOI: 10.1038/msb.2011.71. View

5.
Puri N, Salgia R . Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 2009; 7:9. PMC: 2669728. DOI: 10.4103/1477-3163.44372. View